KPC Pharmaceuticals (600422.SS) Stock Price

KPC Pharmaceuticals Price

SSE·CLOSED
8.36
​
Market closed

Revenue has compounded at 9.6% per year over the past 19 years to 6.58 B CNY. Earnings per share have grown at 30.0% per year over the last 19 years. KPC Pharmaceuticals's net margin stands at 5.3%, broadly stable from 6.2% several years earlier. KPC Pharmaceuticals currently offers a dividend yield of about 3.59%. The payout ratio is around 68% of earnings. The dividend has grown at 18.0% per year over the past 15 years. Analysts set a median price target of 19.12 CNY, implying 128.7% above the current price. Of 9 analysts, 8 rate the stock a buy — an overall Buy consensus.

KPC Pharmaceuticals stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

KPC Pharmaceuticals business model & stock analysis

KPC Pharmaceuticals, Inc. generates revenue through the research, development, manufacturing, and international marketing of its diverse drug portfolio. The company sells natural herbal medicines, traditional Chinese medicines, and chemical synthetic drugs, including central nervous system drugs, cardiovascular and cerebrovascular drugs, anti-parasitic drugs, anti-microbial drugs, anti-gout drugs, hormones and endocrine drugs, hemorrhoids medicines, and anti-inflammatory drugs. Its main customers are healthcare providers, hospitals, and pharmaceutical distributors globally. The firm also produces health products and offers medical services as additional revenue streams. The company's product segments are defined by therapeutic categories such as central nervous system treatments, cardiovascular care, and anti-inflammatory solutions. These products target both domestic and international markets, with a focus on traditional Chinese medicine and natural herbal formulations. Sales are driven by wholesale distribution networks and direct commercial partnerships in the pharmaceutical industry. KPC Pharmaceuticals' revenue model combines product sales from its core drug lines with supplementary health product offerings and medical service provision. The business leverages its manufacturing capabilities in Kunming, Yunnan to serve global markets, with a strong emphasis on traditional Chinese medicine and natural herbal medicine segments. The firm's international marketing efforts support its presence in multiple regions.

Frequently asked questions about KPC Pharmaceuticals

Analysts currently set an average price target of 19.12 CNY for the KPC Pharmaceuticals stock (median: 19.12 CNY), implying +125.7 % versus the latest price. The consensus is based on 9 analyst ratings.

9 analysts currently rate the KPC Pharmaceuticals stock: 8 recommend buying, 1 holding and 0 selling. For 2026, analysts expect KPC Pharmaceuticals to generate revenue of 4.36 B CNY and earnings per share of -0.19 CNY.

Converted at the current exchange rate, the KPC Pharmaceuticals share trades at 1.14 EUR (8.36 CNY).

The KPC Pharmaceuticals share (600422.SS) is listed on 1 stock exchanges, including: Shanghai (600422.SS).

The expected revenue of KPC Pharmaceuticals is 4.36 B CNY. This figure is based on current financial data and reflects the company's business performance.

The expected profit of KPC Pharmaceuticals is -150.72 M CNY. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of KPC Pharmaceuticals is currently -44.28. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the KPC Pharmaceuticals stock.

The price-to-sales ratio (P/S) of KPC Pharmaceuticals is currently 1.53. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the KPC Pharmaceuticals stock.

The Eulerpool Quality Score for KPC Pharmaceuticals is 3/10.

The ISIN of KPC Pharmaceuticals is CNE0000015P8. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of KPC Pharmaceuticals is 600422.SS. The ticker symbol is used to trade KPC Pharmaceuticals shares on the stock exchange.

Fair ValueTerminal
7.27 CNY
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue per Employee
1.24 M CNY
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website kpc.com.cn
Country
Currency
CNY
Initial public offering
Dec 6, 2000
ISIN
CNE0000015P8
Cusip
Y5053T104
Market capitalization
6.30 B CNYMid Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-44.28
P/Ee 2027
35.83
P/Ee 2028
21.81
P/S
P/Se
1.53
EV/EBIT
16.00
P/B Ratio
1.17
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
4.68 %
Dividend
Dividend yield
3.59 %
Est. Dividend Yield
2.15 %
Payout Ratio
68.43 %
Dividend growth Ø5Y
-7.79 %
Dividend payments per year
1
Dividend paid since
7 years
Dividend not reduced since
2 years
Dividend increased since
2 years
Dividend withholding tax
10.00 %
Last updated Nov 17, 2026, 3:42 AM

KPC Pharmaceuticals Peer Group

KPC Pharmaceuticals Ticker

SHH · 600422.SS

KPC Pharmaceuticals FIGI

600422:CH · BBG000DTC2L0600422:CG · BBG000DTC347600422:C1 · BBG00709HQM4